Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ripk4 as a target site in the preparation of drugs for the treatment of bladder cancer

A 1.RIPK4, bladder cancer technology, applied in the field of biomedicine, can solve problems such as unclear clinical and biological significance

Active Publication Date: 2020-04-21
THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical and biological significance of RIPK4 in BUC is largely unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ripk4 as a target site in the preparation of drugs for the treatment of bladder cancer
  • Application of ripk4 as a target site in the preparation of drugs for the treatment of bladder cancer
  • Application of ripk4 as a target site in the preparation of drugs for the treatment of bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] Below in conjunction with accompanying drawing and experimental data, the present invention is further explained and illustrated

[0032] 1. Vector, retrovirus infection and transfection

[0033]The vector pMSCV / RIPK4 overexpressing human RIPK4 was constructed by subcloning the human RIPK4 coding sequence amplified by PCR into the vector pMSCV (Clontech). I cloned four short hairpin RNA (shRNA) oligonucleotides to silence endogenous RIPK4 into the vector pSuper-retro-puro to generate pSuper-retro-RIPK4-shRNA(S). The NF-κB-p65 of the lentiviral ShRNA was constructed, and the ShRNA of the lentiviral VEGF-A was constructed. 48 hours after lentivirus infection, stable expression of RIPK4, RIPK4-ShRNA, NF-κB-p65-ShRNA, and VEGF-A-ShRNA was selected.

[0034] 2. RIPK4 is upregulated in BUC patients

[0035] In order to evaluate the expression model of RIPK4 in BUC, we analyzed the RIPK4 protein level in several BUC cell lines including BIU87, 5637, T24, EJ and RT4 cells, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of RIPK4 as a target site in preparing urinary bladder carcinoma treating medicine. Researches show that RIPK4 in BUC is obviously improved, expression induction ofthe RIPK4 is excessive, and silent RIPK4 can inhibit in-vitro and in-vivo BUC invasion and metastasis. Therefore, the RIPK4 can serve as the target site to be applied to preparing urinary bladder carcinoma treating medicine. In addition, the condition RIPK4 up-regulation can cause vascular endothelial growth factor A (VEGF-A) level increasing is proved, so that the RIPK4 can be applied to preparing target negative regulation VEGF-A expression preparation. Meanwhile, VEGF-A can serve as a target site to be applied to preparing the urinary bladder carcinoma treating medicine.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of RIPK4 as a target site in the preparation of drugs for treating bladder cancer. Background technique [0002] The morbidity and mortality of bladder urothelial carcinoma (BUC) ranks first among urogenital tumors in China. BUC can be divided into non-invasive and invasive subtypes, with the latter having a greater risk of metastasis. Metastatic BUC remains a lethal disease with few therapeutic options other than first-line therapy: the 5-year survival rate for patients with metastatic disease is only 5%. [0003] Multiple signaling pathways have been involved in studying the progression and metastasis of BUC in human bladder tumor specimens and mouse models. Currently, little is known about the precise molecular mechanisms regulating the NF-κB pathway in BUC. Receptor-interacting protein kinase 4 (RIPK4) is a member of the RIP kinase family and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K38/45A61P35/00A61P13/10
CPCA61K38/45A61K45/00C12Y207/11
Inventor 曹科张晔昱何东刘建业曾庆海朱煜星龚恋
Owner THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com